Axitinib (AG-013736)

• CAT Number: A000203
• CAS Number: 319460-85-0
• Molecular Formula: C₂₂H₁₈N₄OS
• Molecular Weight: 386.47
• Purity: ≥95%
• Synonyms: AG 013736
• Target: VEGFR
• Solubility: >19.3mg/mL in DMSO
• Storage: -20°C
• InChI: InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+
• InChIKey: RITAVMQDGBJQJZ-FMIVXFBMSA-N
• SMILES: CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)C=CC4=CC=CC=N4

Axitinib (AG-013736) (Cat No.: A000203) is a potent, selective tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3). It is primarily used in the treatment of advanced renal cell carcinoma. By blocking VEGFR-mediated signaling, Axitinib inhibits angiogenesis, restricting tumor blood supply and growth. Administered orally, it has demonstrated efficacy in patients resistant to prior therapies. Its favorable pharmacokinetic profile allows for rapid absorption and dose titration, making it a valuable option in targeted cancer therapy and angiogenesis research.

Reference

1: Chen Y, Tortorici MA, Garrett M, Hee B, Klamerus KJ, Pithavala YK. Clinical
pharmacology of axitinib. Clin Pharmacokinet. 2013 Sep;52(9):713-25. doi:
10.1007/s40262-013-0068-3. Review. PubMed PMID: 23677771.
2: Kessler ER, Bowles DW, Flaig TW, Lam ET, Jimeno A. Axitinib, a new therapeutic
option in renal cell carcinoma. Drugs Today (Barc). 2012 Oct;48(10):633-44. doi:
10.1358/dot.2012.48.10.1860768. Review. PubMed PMID: 23110259.
3: Carmichael C, Lau C, Josephson DY, Pal SK. Comprehensive overview of axitinib
development in solid malignancies: focus on metastatic renal cell carcinoma. Clin
Adv Hematol Oncol. 2012 May;10(5):307-14. Review. PubMed PMID: 22706540.
4: Escudier B, Gore M. Axitinib for the management of metastatic renal cell
carcinoma. Drugs R D. 2011;11(2):113-26. doi: 10.2165/11591240-000000000-00000.
Review. PubMed PMID: 21679004; PubMed Central PMCID: PMC3585900.
5: Choueiri TK. Axitinib, a novel anti-angiogenic drug with promising activity in
various solid tumors. Curr Opin Investig Drugs. 2008 Jun;9(6):658-71. Review.
PubMed PMID: 18516765.